Guest guest Posted January 10, 2000 Report Share Posted January 10, 2000 this is only a test > Re: MUST READ: transitional states of use > > Bimodal Psychotropic Response to GHB > Ever since the discovery of significant physiologic effects of GHB by Dr. > Henri Laborit over thirty years ago, researchers have been confounded by > government regulators and seemingly anomalous results. Faced with these > two > problems many researchers have abandoned GHB in spite of its obvious > promise. Centurion Aging Research Lab (CARL) has managed to solve the > first > problem, (temporarily at least), and now believe we have an explanation > for > the latter. After years of research on GHB, the Staff at CARL began to > perceive that what at first was considered an anomaly is in fact, a > significant indicator of the potent beneficial effects of Gamma- Hydroxy > Butyrate. > > We first became interested in GHB as an adjunct to our personal life > extension program due to its recognized ability to stimulate growth > hormone > production and initiate restorative stage 4 sleep. Our personal experience > and a review of the literature led to the realization that GHB may be one > of > the most significant life extension agents known, and we determined to > make > its benefits available to the life extention community at large. (See our > page www.ghbinfo.com/getit) It was the universal experience of all our > associates that two to three grams of GHB was sufficient to induce a deep > restorative sleep, and lesser amounts had a pleasant relaxing effect. > > Shortly after the introduction of our G-WiZzZzZ! kit for the safe, at > home, > production of GHB, we became alarmed when several of our customers > complained that the kit products did not have the intended effects. > Instead > of aiding in sleep the product kept them up all night! While it did not > seem > possible, we had to assume that there was a problem with our quality > control, however when samples of the product were returned for analysis > they > proved to be fine. > > The conundrum deepened when a repeat customer called after the purchase of > his third kit to inquire what we had changed. He insisted that something > had > been changed because the product was no longer working. When we inquired > further he replied that GHB was starting to put him to sleep and that it > was > beginning to interfere with his functioning during the day. When informed > that this was the expected effect he responded that he had been taking as > much as four grams three times a day and that it used to make him feel > " energized and almost euphoric " , but now even small amounts were putting > him > to sleep! > > Clearly something very interesting was going on here. We were very much > aware of the significant biochemical individuality of response to GHB, and > of its steep dose/response curve. however we did not believe the phenomena > we were observing could be accounted for in this way. When we went back to > the literature we found that as many as 17% of the individuals in some > controlled studies could not achieve sleep with GHB, but this was > mentioned > as an aside because the studies were investigating growth hormone > production > and not sleep. > > A break came when we received an inquiry from the Netherlands stating that > a > doctor had suggested using GHB as an " AD " . We had no idea what was meant > by > AD and were informed that it meant anti-depressant. Shortly there-after we > received a copy of Dr. Rifat's report and " the light began to dawn " . > Subsequent investigation revealed that every single case of GHB's failure > to > induce sleep that we could account for was associated with a person who > had > either been diagnosed as clinically depressed, or who had strong reason to > think they might be! It is interesting to note that Dr. Rifat admits to > his > own condition as being clinically depressed. > > Dr. Rifat's report contained a number of references to negative > side-effects > of GHB and how to avoid them, which puzzled us. He seemed to consider the > sleep inducing effects of GHB to be negative, while we considered them > positive. He recommends cycling the use of GHB in order to avoid the > induction of sleep. He was also very concerned about the possibility of > GHB > inducing epileptic type seizures, and recommended the prophylactic > administration of benzodiazepenes to protect against them. This was not > only > unnecessary, it actually reduced the effectiveness of GHB therapy, by > producing competition for binding sites. The fear of epileptic type > seizures > is based on animal studies and has since been shown to not apply to > humans. > > It is now clear that there is a bimodal psychotropic response to GHB. Most > people experience relaxation and deep sleep within 45 minutes in response > to > 3.5g or less of GHB, we refer to this as the Somnolent GHB Response (SGR). > A > smaller population composed of clinically depressed individuals experience > euphoria and complete alleviation of depression at the same dose and in > the > same period of time. We call this the Euphoric GHB Response (EGR). This > bimodal response to GHB means that for the first time there may be a > definitive, objective test for clinical depression. > > Observations indicate that most depressed individuals undergo a change in > their response to GHB that corresponds with a long-term and possibly > permanent lifting of their depression. This shift in response usually > occurs > in 30 to 90 days with a few individuals reporting the change within a week > and one who has still not experienced it after five months. There is some > evidence that caffeine may slow or inhibit the transition. It is tempting > to > think of such long term change in terms of a " cure! " Unfortunately, Rifat > and others have apparently misinterpreted the change in response to GHB in > a > negative light and have instituted protocols to prevent it from occurring, > rather than encouraging it. > > For those health professionals who are working with GHB or would like to, > we > suggest the following protocol. If an individual is experiencing symptoms > of > depression administer two grams of GHB on an empty stomach. It is strongly > advised that this be done at a time when either potential response (SGR or > EGR) will not present a problem. If no subjective effects are experienced > within an hour, administer another 1.5 grams. If the subject feels > anything > other than very tired or " drunk " they are not experiencing the expected > Somnolent GHB Response (SGR), and have EGR, or are experiencing > Transitional > GHB Response (TGR). We suggest that individuals in EGR work with their > health care professional to determine optimal dosing which will vary with > the severity of the symptoms and which will decline over time. One > psychiatrist reported doses as high as 12 grams a day being required to > eliminate all undesirable symptoms, and that this dose declined to 6/g/day > within two weeks. > > Once the transition from EGR to SGR begins to occur it is important > individuals stop taking GHB at times when drowsiness or sleep are > unwanted. > A person experiencing EGR will exhibit heightened alertness and powers of > concentration which are advantages in many situations, and it is not > surprising that a person would view the loss of these effects as negative. > It is important that they realize that increased or repeated dosing will > not > effect the return of such subjective effects and will in fact produce the > opposite result. As the EGR declines individuals should decrease and > eventually eliminate their daytime dosing and switch to a " maintenance > regime " of two to three grams at bed time. > > These observations, interpretations, hypothesis, and recommendations are > presented as a public service by Centurion Aging Research Laboratory, in > the > hope that they will spur further research, alleviate human suffering and > enrich the experience of life. They are based on our personal experience > and > the experience of those who have been kind enough to report to us. This > report should not be construed as containing medical advice and has most > certainly NOT been approved by the FDA. We strongly discourage anyone from > beginning ANY program of personal experimentation without the consent and > advice of their health care professional. We would like to encourage > anyone > who has had positive or negative experiences with GHB to share them with > us. > reprint from: http://lab.eccentrica.org/ghb/bimodal.html > > Happy Holidays! > Tom > > Re: Kidney damage?!! > > > > Thanks Dr . > > > > It looks like the evidence is stacking up in favor of GHB and against > GBL, > > in terms of both safety and benefits, which is very ironic considering > that > > GBL is legal but GHB is not. Thanks for nothing Uncle Sam. > > > > -gts > > > > > > ------------------------------------------------------------------------ > Want to send money instantly to anyone, anywhere, anytime? > You can today at X.com - and we'll give you $20 to try it! Sign > up today at X.com. It's quick, free, & there's no obligation! > 1/332/5/_/164625/_/945832028 > > eGroups.com Home: longevity/ > - Simplifying group communications > Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.